News

At least 800 people representing some 45 countries are soon expected to gather in Austria’s capital city, Vienna, for ECRD 2018, the 9th European Conference on Rare Diseases and Orphan Products. The May 10-12 meeting is sponsored by Eurordis, the Paris-based group that defines itself as a “patient-driven alliance”…

Patients with cardiac sarcoidosis have similar post-heart transplant features and survival rates as patients without the disease, a new study found. The data indicates that heart transplant is a viable strategy in patients with cardiac sarcoidosis. Although heart transplants due to non-ischemic cardiomyopathy (NICM; when the heart’s muscle —…

Exposure to chemical substances used in leather tanning may have been the cause of a rare case of subcutaneous (under-the-skin) sarcoidosis around a man’s left eye and mouth, a recent case report suggests. The report, “Occupational exposure as a presumable cause of subcutaneous sarcoidosis in a tannery…

The Foundation for Sarcoidosis Research (FSR) has invested $1 million in its new Clinical and Research Fellowship Program. It also gave travel awards to the first authors of the top four abstracts submitted for presentation at the annual conference of the Americas Association of Sarcoidosis and Other Granulomatous Disorders…

The Foundation for Sarcoidosis Research is calling for everyone to participate this month of April in a campaign to celebrate those living with sarcoidosis. This year’s campaign, #SarcoidStories, is an effort to raise awareness among the general public about the daily challenges and joys in the lives of…

A little-known government entity within the National Institutes of Health (NIH) is helping to lead U.S. efforts to speed up the development of therapies for some 7,000 rare diseases. The Office of Rare Diseases Research (ORDR), headquartered in Bethesda, Maryland, was established in 1993 within the NIH Office of the…

The American Lung Association, CHEST Foundation and the Foundation for Sarcoidosis Research (FSR) teamed up to bring greater awareness to sarcoidosis and encourage patients to be more proactive in their treatment programs. The joint effort,…

A recent study found that migraines are at least as common in patients with sarcoidosis as they are in the general public, and they affect women more than men. The study’s authors highlighted the need for better recognition and targeted treatment of migraine in people with sarcoidosis. The study, “…

A wearable cardioverter-defibrillator can prevent sudden death in patients with cardiac sarcoidosis, new research demonstrates. A study found the device was capable of restoring heart rhythm in all patients who experienced abnormal and potentially life-threatening heartbeats. Results were reported in the study,…

Bardoxolone methyl, an investigational therapy developed by Reata Pharmaceuticals, was shown to significantly improve the exercise capacity of patients with pulmonary hypertension (PH) associated with sarcoidosis in a Phase 2 clinical trial. Bardoxolone is an experimental, oral molecule that promotes the resolution of inflammation by targeting an important mediator…